May 31, 2016 6:34 PM ET

Biotechnology

Company Overview of Agios Pharmaceuticals, Inc.

Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company’s product candidates include AG-221, an potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II, Phase Ib combination, and Phase III IDHENTIFY clinical trials for the treatment of hematologic malignancies, as well as is in Phase 1/2 clinical trial for treating solid tumors, including AITL. Its product candidates also comprise AG-120, an potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical and Phase Ib combination clinical tr...

88 Sidney Street

Cambridge, MA 02139

United States

Founded in 2007

208 Employees

Phone:

617-649-8600

Key Executives for Agios Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 58
Total Annual Compensation: $517.5K
Principal Financial Officer and Senior Vice President of Finance
Age: 44
Total Annual Compensation: $318.3K
Chief Medical Officer
Age: 54
Total Annual Compensation: $553.8K
Chief Scientific Officer
Age: 59
Total Annual Compensation: $400.9K
Compensation as of Fiscal Year 2015.

Agios Pharmaceuticals, Inc. Key Developments

Agios Pharmaceuticals, Inc., 2016 Guidance/Update Call, May 17, 2016

Agios Pharmaceuticals, Inc., 2016 Guidance/Update Call, May 17, 2016

Agios Pharmaceuticals, Inc. and Celgene Corporation Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement

Agios Pharmaceuticals, Inc. and Celgene Corporation announced an agreement creating a new global strategic collaboration focused on metabolic immuno-oncology, an emerging field of cancer research focused on altering the metabolic state of immune cells to enhance the body’s immune response to cancer. The goal of the collaboration is to discover, develop and commercialize novel therapies based on Agios’ innovative cellular metabolism research platform. Agios will receive an upfront cash payment of $200 million plus the potential for additional payments if certain development and regulatory milestones are achieved. Also announced, the companies modified certain rights from their 2010 collaboration. First, Agios, which previously held U.S. rights for AG-120, gained global development and commercialization rights to the program from Celgene. As of August 15, 2016, neither party will have financial or other obligations to each other related to AG-120. There are no other changes to the existing IDH partnership between Agios and Celgene. Second, the companies agreed that rights to two cancer metabolism programs discovered under the 2010 Agreement, including a program focused on MTAP (methylthioadenosine phosphorylase) deleted cancers, will advance under the structure of the new research collaboration outlined below. Following the expiration of the discovery phase of the 2010 Agreement on April 14, 2016, all other cancer metabolism programs discovered at Agios will remain wholly owned by Agios. Metabolic immuno-oncology is a rapidly evolving scientific area focused on altering the metabolic state of immune cells, or the tumor microenvironment, to enhance the body’s immune response to cancer. There is increasing evidence that metabolism plays an important role in the regulation of immune cells and their response to tumors. The collaboration aims to discover novel metabolic pathways and their modulators that affect the metabolic state of immune cells, which may serve as potent anticancer therapies. In addition, Agios will focus on discovering molecular markers in order to identify patients who are most likely to respond to therapies.

Agios Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2016; Provides the Updates on Its Clinical Development Programs in Collaboration with Celgene

Agios Pharmaceuticals, Inc. reported unaudited consolidated results for the first quarter ended March 31, 2016. For first quarter, the company reported collaboration revenue of $31,281,000 against $34,202,000 a year ago. Loss from operations was $23,594,000 against $5,195,000 a year ago. Net loss was $23,198,000 or $0.61 basic and diluted loss per share against $4,957,000 or $0.13 basic and diluted loss per share a year ago. Agios provided updates on its clinical development programs in collaboration with Celgene. IDH Mutant Inhibitors in Hematologic Malignancies; completed enrollment of the Phase 2 expansion cohort for the Phase 1/2 study of AG-221 in patients with R/R AML in May 2016, Initiated a Phase 1/2 frontline combination study of AG-221 or AG-120 with VIDAZA(azacitidine) in newly diagnosed AML patients not eligible for intensive chemotherapy in March 2016, Received EMA Orphan Drug Designation for AG-221 for the treatment of AML in April 2016. Cancer Metabolism Research: In April, Agios published preclinical findings from its program focused on MTAP (methylthioadenosine phosphorylase) deleted cancers in the peer-reviewed journal Cell Reports. IDH Mutant Inhibitors in Hematologic Malignancies: Complete enrollment of the 125-patient expansion cohort for the Phase 1 study of AG-120 in patients with R/R AML in the second half of 2016, Initiate a global, registration-enabling Phase 3 study of AG-120 in frontline AML patients with an IDH1 mutation in the second half of 2016, Initiate an expansion arm in high-risk myelodysplastic syndrome patients for AG-221 in 2016, Continue to enroll patients in the following ongoing clinical trials: Phase 3 IDHENTIFY study of AG-221 vs. standard of care chemotherapy in R/R AML, Phase 1b frontline combination study of AG-221 or AG-120 with standard-of-care intensive chemotherapy in AML, Phase 1/2 frontline combination study of AG-221 or AG-120 with VIDAZA® in AML, Phase 1 dose-escalation and expansion study of AG-881 in IDH mutant positive hematologic malignancies. IDH Mutant Inhibitors in Solid Tumors: Present data from the expansion phase of the ongoing Phase 1 study of AG-120 in advanced IDH1 mutant positive low-grade glioma in the second half of 2016, Initiate a randomized Phase 2 study of AG-120 in IDH1 mutant positive cholangiocarcinoma in the second half of 2016, Continue to enroll patients in the following ongoing clinical trials: Expansion phase of the ongoing Phase 1 study of AG-120 in advanced IDH1 mutant positive solid tumors, Phase 1 dose-escalation and expansion study of AG-881 in IDH mutant positive solid tumors. Cancer Metabolism Research: Initiate preclinical development activities for the first molecule in the MTAP program in 2016.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States
3D Biomatrix Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Agios Pharmaceuticals, Inc., please visit www.agios.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.